Cell Medica is a London-based biotech which develops, manufactures and markets personalised cell immunotherapeutics for infectious disease and cancer. It has therefore just acquired a Swiss antibody manufacturing biotech Delenex, to help its progress into the CAR-T field.
Update 20/07/16: Cell Medica has also just received EMA Orphan Drug Designation for their CMD-003 candidate. This means it can obtain regulatory and financial incentives for developing and marketing CMD-003, along with a ten-year period of marketing exclusivity within the EU after product approval.
Delenex is based in Schlieren (Switzerland) and manufactures locally and systemically applied antibody therapeutics. Founded in September 2009, it was a spin-off from Zurich’s ESBATech (now a Novartis company).
On the other hand, Cell Medica is working in collaboration with the Baylor College of Medicine in Texas to develop next-generation cellular immunotherapies incorporating chimeric antigen receptors (CAR).